

## Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study

Eduard J. van Beers,<sup>1</sup> Stephanie van Straaten,<sup>1</sup> D. Holmes Morton,<sup>2</sup> Wilma Barcellini,<sup>3</sup> Stefan W. Eber,<sup>4</sup> Bertil Glader,<sup>5</sup> Hassan M. Yaish,<sup>6</sup> Sathesh Chonat,<sup>7</sup> Janet L. Kwiatkowski,<sup>8</sup> Jennifer A. Rothman,<sup>9</sup> Mukta Sharma,<sup>10</sup> Ellis J. Neufeld,<sup>11</sup> Sujit Sheth,<sup>12</sup> Jenny M. Despotovic,<sup>13</sup> Nina Kollmar,<sup>14</sup> Dagmar Pospíšilová,<sup>15</sup> Christine M. Knoll,<sup>16</sup> Kevin Kuo,<sup>17</sup> Yves D. Pastore,<sup>18</sup> Alexis A. Thompson,<sup>19</sup> Peter E. Newburger,<sup>20</sup> Yaddanapudi Ravindranath,<sup>21</sup> Winfred C. Wang,<sup>11</sup> Marcin W. Wlodarski,<sup>22</sup> Heng Wang,<sup>23</sup> Susanne Holzhauer,<sup>24</sup> Vicky R. Breakey,<sup>25</sup> Madeleine Verhovsek,<sup>25</sup> Joachim Kunz,<sup>26</sup> Melissa A. McNaull,<sup>27</sup> Melissa J. Rose,<sup>28</sup> Heather A. Bradeen,<sup>29</sup> Kathryn Addonizio,<sup>30</sup> Anran Li,<sup>30</sup> Hasan Al-Sayegh,<sup>30</sup> Wendy B. London<sup>30</sup> and Rachael F. Grace<sup>30</sup>

<sup>1</sup>Van Creveldekliniek, University Medical Centre Utrecht, University of Utrecht, the Netherlands; <sup>2</sup>Central Pennsylvania Clinic for Special Children & Adults, Belleville, PA, USA; <sup>3</sup>Lancaster General Hospital, Lancaster, PA, USA; <sup>4</sup>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy; <sup>5</sup>Schw-erpunktepraxis für Pädiatrische Hämatologie-Onkologie and Children's Hospital, Technical University, Munich, Germany; <sup>6</sup>Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA, USA; <sup>7</sup>Primary Children's Hospital, University of Utah, Salt Lake City, UT, USA; <sup>8</sup>Emory University School of Medicine, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, GA, USA; <sup>9</sup>Children's Hospital of Philadelphia and Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA; <sup>10</sup>Duke University Medical Center, Durham, NC, USA; <sup>11</sup>Children's Mercy Hospital, University of Missouri, Kansas City, MO, USA; <sup>12</sup>St. Jude Children's Research Hospital, Memphis, TN, USA; <sup>13</sup>Weill Cornell Medical College, New York Presbyterian Hospital, NY, USA; <sup>14</sup>Texas Children's Hematology Center, Baylor College of Medicine, Houston, TX, USA; <sup>15</sup>Klinikum Kassel GmbH, Germany; <sup>16</sup>Fakultni nemocnice Olomouc, Czech Republic; <sup>17</sup>Phoenix Children's Hospital, AZ, USA; <sup>18</sup>University of Toronto, University Health Network, ON, Canada; <sup>19</sup>CHU Sainte-Justine, Montreal, QC, Canada; <sup>20</sup>Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA; <sup>21</sup>University of Massachusetts Medical School, Worcester, MA, USA; <sup>22</sup>Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI, USA; <sup>23</sup>Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Germany; <sup>24</sup>DDC Clinic for Special Needs Children, Middlefield, OH, USA; <sup>25</sup>Charité, Berlin, Germany; <sup>26</sup>McMaster University, Hamilton, ON, Canada; <sup>27</sup>Zentrum für Kinder-und Jugendmedizin, University of Heidelberg, Heidelberg, Germany; <sup>28</sup>University of Mississippi Medical Center, Jackson, MS, USA; <sup>29</sup>Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH, USA; <sup>30</sup>The University of Vermont Children's Hospital, Burlington, VT, USA and <sup>30</sup>Dana-Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA, USA

Correspondence: rachael.grace@childrens.harvard.edu  
doi:10.3324/haematol.2018.196295

**SUPPLEMENTAL TABLE**

**Supplemental Table 1: Patient characteristics, comparing those with iron monitoring to those without monitoring, in the 12 months prior to enrollment.**

	Ferritin monitoring (n=242)			MRI monitoring for liver iron assessment, in the non-Amish patient cohort (n=189)		
	Obtained in the 12 months prior to enrollment (n=175)*	Not obtained in the 12 months prior to enrollment (n=67)*	p-value**	Obtained in the last 12 months prior to enrollment (n=18)*	Not obtained in the last 12 months prior to enrollment (n=171)*	p-value**
Median*** Age at enrollment	21.8 (1.3-69.9)	16.3 (1.4-60.4)	0.3	21.1 (2.2-46.0)	19.1 (1.3-69.9)	0.5
Transfused in the 12 months prior to enrollment (%)	72/175 (41%)	9/67 (13%)	<0.0001	11/18 (61%)	67/171 (39%)	0.08
Regularly Transfused (%)	43/175 (25%)	1/67 (1%)	<0.0001	7/18 (39%)	36/171 (21%)	0.1
Median*** Hemoglobin value (g/dl)	8.8 (5.2-14.1) n=174	9.6 (6.5-13.0) n=65	0.01	8.6 (6.2-11.1)	8.7 (5.2-14.1) n=168	0.3
Splenectomized (%)	112/175 (64%)	37/67 (55%)	0.2	15/18 (83%)	83/171 (49%)	0.006

\*Number of patients with known data (n) are presented in the column headers unless otherwise indicated in the table. \*\*Using Fisher's exact test for categorical variables and Wilcoxon rank-sum test for continuous variables. \*\*\*Median presented with ranges.